drugset / Trial / NCT05162326
BC-101 in Treatment of Nasolabial Fold Wrinkles
NaSequentialOpen-labelTreatment
Summary
This is an open-label, single-arm, dose-escalating study to evaluate the safety and tolerability of BC-101 administered via subcutaneous/intradermal injection in the treatment of moderate to severe nasolabial folds.
Timeline
- Start
- 2026-12-01
- Primary completion
- 2027-12-30
- Completion
- 2028-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC-101 | Cell therapy | 2 unknown | Subcutaneous |
| Subject | BC-101 | Cell therapy | 4 unknown | Subcutaneous |
| Subject | BC-101 | Cell therapy | 6 unknown | Subcutaneous |
Indications
No indication recorded.